Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.57 |
| ▸ | MTOR | P42345 | 3/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.46 |
| ▸ | CD99 | P14209 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | THPO | P40225 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | CDA | P32320 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17972348 | 1.00 | LMNA (0.57) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL21418706 | 1.00 | LMNA (0.57) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL26976391 | 1.00 | LMNA (0.57) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL17976764 | 1.00 | LMNA (0.57) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL16576161 | 0.90 | LMNA (0.57) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL17972246 | 0.90 | LMNA (0.57) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL30664789 | 0.88 | LMNA (0.72) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL288517 | 0.88 | LMNA (0.72) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL6302404 | 0.88 | LMNA (0.72) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL42103 | 0.88 | LMNA (0.72) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | LMNA 2780/4885MTOR 2965/4885THRB 2429/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | LMNA 1285/4885MTOR 1701/4885THRB 4511/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | LMNA 2417/4885MTOR 2992/4885THRB 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.